Miyamoto, Atsushi http://orcid.org/0000-0002-3444-0536
Michimae, Hirofumi
Nakahara, Yasuharu
Akagawa, Shinobu
Nakagawa, Kazuhiko
Minegishi, Yuji http://orcid.org/0000-0001-5023-8058
Ogura, Takashi
Hontsu, Shigeto
Date, Hiroshi http://orcid.org/0000-0001-7262-6000
Takahashi, Kazuhisa http://orcid.org/0000-0001-5749-4118
Homma, Sakae
Kishi, Kazuma
,
Nakahara, Y.
Ohta, K.
Gemma, A.
Nishizaka, Y.
Ogura, T.
Kimura, H.
Nishi, K.
Nakamura, M.
Yokomura, K.
Taniguchi, H.
Tomii, K.
Shindo, J.
Sato, K.
Taguchi, Y.
Takahashi, H.
Takizawa, H.
Homma, S.
Nakamura, S.
Yoshimura, K.
Usui, K.
Ichikado, K.
Bessyo, A.
Sugiyama, H.
Hasegawa, Y.
Nakamura, H.
Sagara, H.
Ube, K.
Nomura, F.
Kiura, K.
Yoshiike, F.
Takahashi, K.
Kita, T.
Sakai, H.
Bando, M.
Matsumoto, T.
Inoue, T.
Kijima, T.
Mukae, H.
Masuda, N.
Matsumoto, N.
Sakamaki, F.
Kamimura, M.
Takise, A.
Kishaba, T.
Nishioka, Y.
Kashiwabara, K.
Yamamoto, A.
Fujiuchi, S.
Shingyoji, M.
Hanaoka, M.
Tominaga, S.
Kadota, J.
Kasahara, T.
Motegi, M.
Harada, T.
Ishikawa, S.
Suda, T.
Tomizawa, Y.
Hayashi, R.
Shinoda, M.
Terada, M.
Jin, Y.
Shikama, Y.
Kikuchi, T.
Kido, K.
Yokoyama, A.
Fuke, S.
Nagase, H.
Tanaka, H.
Hizawa, N.
Miyazaki, K.
Ikushima, S.
Sakai, N.
Hoshino, T.
Mishima, M.
Ohnishi, H.
Imai, H.
Nagashima, S.
Kojima, E.
Ohishi, S.
Ohe, Y.
Iwakami, S.
Mineshita, M.
Komase, Y.
Harada, H.
Imokawa, S.
Watanabe, H.
Ichiki, M.
Kuwano, K.
Takahashi, N.
Chonabayashi, N.
Hisada, T.
Yoshida, M.
Hirata, K.
Watanabe, K.
Sugino, Y.
Yoshioka, S.
Tomioka, H.
Aoshima, M.
Sugimoto, Y.
Ichinose, M.
Tamaki, S.
Tsuchiya, M.
Katayama, H.
Okochi, Y.
Tanaka, H.
Ogata, K.
Tsuburai, T.
Honda, I.
Clinical trials referenced in this document:
Documents that mention this clinical trial
Acute exacerbation predicting poor outcomes in idiopathic interstitial pneumonia and advanced lung cancer patients undergoing cytotoxic chemotherapy
https://doi.org/10.1038/s41598-024-60833-w
Article History
Received: 30 December 2023
Accepted: 28 April 2024
First Online: 3 May 2024
Competing interests
: Atsushi Miyamoto received a lecture fee from Boehringer Ingelheim Japan Inc.; Takashi Ogura received honoraria for lectures, presentations, speakers, bureaus, manuscript writing, or educational events from Japan Boehringer Ingelheim and Shionogi Co., and participating on the data safety monitoring board or advisory board of BMS, Japan Boehringer Ingelheim, and Taiho Pharmaceutical Co., Ltd.; Yuji Minegishi received honoraria for lectures, presentations, speakers, bureaus, manuscript writing, or educational events from AstraZeneca K.K., Eli Lilly Japan K.K., Chugai Pharmaceutical Co. Ltd., Bristol-Myers Squibb Company, Takeda Pharmaceutical Co. Ltd., Eisai Co. Ltd., Boehringer Ingelheim Japan Inc., Taiho Pharmaceutical Co. Ltd., Ono Pharmaceutical Co. Ltd., Daiichi-Sankyo Co. Ltd., and Nippon Kayaku Co. Ltd.; Kazuhisa Takahashi received honoraria for lectures, presentations and speakers from Nippon Boehringer Ingelheim Co. Ltd., MSD K.K., Pfizer Inc., AstraZeneca K.K., TAIHO PHARMACEUTICAL CO., LTD., KYORIN Pharmaceutical Co., Ltd., Merck Biopharma Co., Ltd., ONO PHARMACEUTICAL CO., LTD., Nippon Kayaku Co., Ltd., Novartis Pharma K.K., Eli Lilly Japan K.K., Sumitomo Dainippon Pharma Co., Ltd., Bristol Myers K.K., Meiji Seika Pharma Co., Ltd., Takeda Pharmaceutical Company Limited., Viatris Inc., Janssen Pharmaceutical K.K., Abbott Japan LLC., Thermo Fisher Scientific Inc. and Chugai Pharmaceutical Co., Ltd.; grants from NIPPON SHINYAKU CO., LTD., TSUMURA & CO., Pfizer Inc., ONO PHARMACEUTICAL CO., LTD., Novartis Pharma Inc., SHIONOGI & CO., LTD., DAIICHI SANKYO Co., LTD., NIPRO PHARMA CORPORATION, Asahi Kasei Pharma Corporation, Nippon Kayaku Co., Ltd., Takeda Pharmaceutical Co., Ltd., Kyowa Kirin Co., Ltd., Bayer Yakuhin, Ltd, Chugai Pharmaceutical Co., Ltd., Eli Lilly Japan K.K., KYORIN Pharmaceutical Co., Ltd., Nippon Boehringer Ingelheim Co., Ltd., Sanofi K.K., TAIHO PHARMACEUTICAL CO., LTD., and TEIJIN PHARMA LIMITED; leadership role in society, committee or advocacy group of the Japan Lung Cancer Society and the Japanese Respiratory Society.; Hirofumi Michimae, Yasuharu Nakahara, Shinobu Akagawa, Kazuhiko Nakagawa, Yuji Minegishi, Shigeto Hontsu, Hiroshi Date, Sakae Homma, and Kazuma Kishi have no conflicts of interest.